Navigation Links
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
Date:4/3/2012

al information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of April 4, 2012 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Mettler-Toledo International Inc. (NYSE: MTD ) ... are the highlights: , Sales in local ... prior year. Reported sales decreased 4% as currency reduced ... Net earnings per diluted share as reported (EPS) were ... EPS was $2.80 , an increase of 9% ...
(Date:7/30/2015)... July 30, 2015  EP Global Communications, Inc. (Public ... recently contacted the Company about discussing EPGL,s electronic ... as Monday, August 3, 2015.  Novartis CEO ... that the coming electronic contact lens market could ... the next several years.  Novartis partnered with Google ...
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the second quarter ending June 30, 2015. ... the organization.  We are excited to be near the ... ever conducted with topline results expected in the fourth ... PTC Therapeutics, Inc. "Translarna is now commercially available in ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2015 Results 14PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: ... Cytometer, a flexible, reliable and scalable system that can analyze ... research applications.   “We engineered cutting-edge innovation ... three foundations in mind,” said James Glasscock, President of Cell ...
... 2011 Ann Arbor SPARK recently celebrated the conclusion of ... a reception.  At the Ann Arbor SPARK Boot Camp Celebration, ... Camp" winner, based on the quality of its investor pitch ... though the Ann Arbor SPARK Business Accelerator.   ...
Cached Medicine Technology:BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow 2BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow 3Brio Device Awarded Best of Ann Arbor SPARK's Boot Camp 2
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased to announce a ... Q-Suite is their flagship contact center ACD system for Asterisk-based call centers . ... shows the script components to the agent only when wanted, and allows for validation ...
(Date:7/31/2015)... Minneapolis, Minn. (PRWEB) , ... July 31, 2015 ... ... software, is selected as a contributor for LeadingAge’s Center for Aging Services Technologies ... studies designed to help long-term and post-acute care providers understand the benefits of ...
(Date:7/31/2015)... ... July 31, 2015 , ... The ... Karmanos Center for Natural Birth . The Karmanos Center for Natural Birth ... childbirth experience. With nurses and caregivers that are trained in holistic birth approaches, ...
(Date:7/31/2015)... OR (PRWEB) , ... July 31, 2015 , ... New ... Granary District Stage Amphitheater in McMinnville, Oregon August 15th, 2015 from 9am – 12pm. ... an exciting and important day for the entire community as the culmination of months ...
(Date:7/31/2015)... ... July 31, 2015 , ... An ... from NBC talked about a woman’s unfortunate experience having cosmetic skin procedures done ... face, which resulted in blistering, swelling, bruising, and pain. This woman’s experience is ...
Breaking Medicine News(10 mins):Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3
... 2012)When combined with other treatments, the drug cetuximabwhich works ... been shown to extend survival in certain types of ... percent of colorectal cancer patientsspecifically those who carry a ... to the drug. Researchers at Fox Chase Cancer ...
... the next generation of global health scientists, Fogarty International ... Health are building a network of U.S. academic institutions ... a significant mentored research experience in a developing country. ... over the next five years to support 400 early-career ...
... autoimmune diseases also display a tendency to develop atherosclerosis ... arteries. Clinical researchers at LMU, in collaboration with colleagues ... to explain the connection between the two types of ... of immune cells called plasmacytoid dendritic cells (pDCs). pDCs ...
... ,People with metal-on-metal hip replacements do not have an increased ... receive the device, according to a new study. However, ... Universities of Bristol and Exeter in the U.K. report. ... and Wales, which contains records on more than 1 million ...
... News) -- A new study finds that preteen girls ... experience side effects after receiving the human papillomavirus (HPV) vaccine, ... are similar to those associated with other vaccines. U.S. ... to 26, within two weeks after they received the Gardasil ...
... April 3 (HealthDay News) -- Adding the drug cetuximab (brand ... colon cancer did not improve disease-free survival in patients, a ... who undergo surgery have a 50 percent chance of cure, ... leucovorin, fluorouracil and oxaliplatin (a regimen known as FOLFOX) after ...
Cached Medicine News:Health News:Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance 2Health News:NIH awards $20 million over 5 years to train next generation of global health researchers 2Health News:NIH awards $20 million over 5 years to train next generation of global health researchers 3Health News:The long arm of the dendritic cell 2Health News:The long arm of the dendritic cell 3Health News:No Added Cancer Risk From Hip Replacement Materials: Study 2Health News:Preteens More Likely to Report HPV Vaccine Side Effects 2Health News:Experimental Chemo Combo for Colon Cancer Disappoints 2
... tasks and delivers consistently reliable ... and ensure testing accuracy in ... automated reticulocyte counts and three-dimensional ... sensitivity, specificity and efficiency in ...
... staff scheduling solution that streamlines and ... the synchronization and interface of workforce ... maintains staff schedules and replacements; tracks ... shift and work location schedules; and ...
... A first of its kind product, ... most appealing colors and state-of-the-art SPECT technology ... cardiology system. The exclusive, contoured patient chair ... cardiac scanning. A relaxed patient moves ...
... Series of Cryoablation Catheters combines the safeguard ... the two-stage cooling system of the CryoCor ... of cryoenergy to the ablation site. CryoCor's ... create the transmural lesions necessary to permanently ...
Medicine Products: